Immature myeloid precursor cells were preferentially selected from normal human bone marrow by using immune rosette techniques that employed monoclonal antibodies against mature granulocytes, monocytes, T and B lymphocytes, and erythroid precursors (Mo5, M3, OKT3, Bi, and EPi, respectively). We examined the formation, retention, and cytotoxic effects of methotrexate (MTX) polyglutamates (MTX-PGs) in these purified myeloid precursor cells. After 1-and 24-h exposures to MTX, with thymidine and deoxyinosine as rescue, the intracellular MTX-PG profile was examined by high-pressure liquid chromatography. Efflux patterns of MTX-PGs were also studied after additional 1-and 24-h incubations in drug-free media. Cytotoxic effects of retained MTX-PGs on bone marrow myeloid precursors were examined by colony formation in drug-free semisolid agar.
Introduction
Methotrexate (2,4-diamino,10-methylpteroyl glutamic acid; MTX or MTX-Glul)' is a potent inhibitor of dihydrofolate 1 . Abbreviations used in this paper: CFU-C, colony-forming unit in culture; DHFR, dihydrofolate reductase; FCS, fetal calf serum; MEM-AB, Eagle's minimum essential medium containing 2.5% pooled reductase (DHFR) and has shown consistent clinical antitumor activity (1, 2) . Like the physiologic folate cofactors (3), MTX is converted by various tissues to poly-'y-glutamyl derivatives containing two to five glutamyl residues (MTX-PGs); this metabolic pathway has been demonstrated to be operative in vivo in a variety of normal and malignant cells, including human erythrocytes (4) and liver (5) , and murine intestinal mucosa and tumors (6) (7) (8) (9) , and in vitro in human fibroblasts (10) and bone marrow aspirates (1 1), L12 10 murine leukemia cells (12) , Ehrlich ascites tumor cells (13) , and rat hepatocytes and hepatoma cells (14) (15) (16) . In previous studies we have examined the formation, retention, and pharmacologic effects of MTX-PGs in human breast cancer cell lines, using a highly specific high-pressure liquid chromatography analytic system that allows precise identification of chain length of the MTX derivatives (17) (18) (19) . These studies showed that the polyglutamate derivatives with two to five y-linked glutamyl moieties (MTX-Glu2 to MTX-GIu5) are selectively retained by cells after removal of extracellular drug. The degree of retention of these derivatives correlates directly with glutamyl chain length. MTX-PG retention was shown to prolong the cytotoxic action of this drug. Furthermore, in three patient-derived small-cell lung cancer cell lines, MTX responsiveness was closely related to the ability of cells to accumulate and retain the longer glutamyl chain derivatives (MTX-Glu3, -Glu4, and -Glu5) in excess of intracellular binding capacity (20) . Such higher molecular weight MTX-PGs have high affinity for DHFR and provide prolonged inhibition of DNA synthesis and cell growth.
Although there have been a number of studies of preferential retention of MTX-PGs in tumor cell lines, little is known about their formation and retention in normal human tissues. Using the mononuclear cell fraction from mouse bone marrow, Fabre et al. (21) found little evidence of MTX-PG formation after a 2-h incubation with 5 MM MTX and no depression of myeloid colony formation (CFU-C). In further studies, Fry et al. (22) was further supplemented with 10 MM thymidine and 10 MM deoxyinosine. This medium containing rescue nucleosides protected myeloid precursor cells from the cytotoxic action of MTX. After 1 or 24 h of incubation, cells were harvested to determine total intracellular drug and metabolite levels. Drug bound to intracellular target enzyme and free drug were separated by DEAE-Sephacell chromatography as described previously (18) . In some experiments, at the end of the 24-h drug incubation, remaining cells were washed twice with 5 ml of phosphate-buffered saline and resuspended in an equal volume of drug-free complete media and incubated at 370C for an additional 1 or 24 h in order to determine drug efflux patterns. At each time point, cells were processed for intracellular polyglutamate formation by highpressure liquid chromatography as described previously (18) . Drug levels were expressed as nanomoles of MTX/gram of protein as determined by the method of Lowry et al. (29) .
CFU-C assay for cytotoxicity studies. In order to determine the effects of retained drug on CFU-C formation, separate aliquots of 2 X lo, purified MPCs were incubated for 24 h in complete media containing 1 or 10 MM MTX with thymidine and deoxyinosine. After incubation, cells were washed twice in 5 ml of PBS and resuspended in the initial volume. CFU-C assays were performed using a soft-agar method originally described by Pike and Robinson (30) . Cells, 1-2 X 104 per plate, were cultured in 0.3% agar in drug-free and rescuefree McCoy's 5A medium supplemented with 20% dialyzed FCS and 10% dialyzed and partially purified colony-stimulating factor from the conditioned medium of thyroid cancer cells (CSF-Chugai) (31) . After 10 d of incubation at 37°C in a humidified atmosphere of 5% CO2 in air, colonies (240 cells) and clusters (8-39 cells) were enumerated using an inverted microscopy.
Results
Cell preparation. Treatment with the panel of monoclonal antibodies, followed by SRBC rosetting, reduced the number of mononuclear cells to 2.2±0.9% (mean± 1 SD) of the number harvested. Marked changes in the population distribution were observed, as shown in Table I and Fig. 1 . Mature granulocytes (from myelocytes through polymorphonuclear leukocytes) decreased from 43±15% of the initial bone marrow aspirate population to only 12±6% of the cells in the purified fraction. T and B lymphocytes, monocytes, and erythroid precursors were virtually eliminated. Most notably, immature myeloid cells, including undifferentiated blasts and promyelocytes, increased from 4±2% to 80±23% of the total cell population. These changes were associated with a 6-to 26-fold increase in cloning efficiency in the CFU-C assay. MTX uptake, polyglutamation, and retention studies were performed on this purified MPC population.
Intracellular MTX-PG formation. The uptake and retention 24-h efflux periods in drug-free media (Tables II and III) . Drug levels at each time point are also expressed as percent saturation of intracellular binding capacity, as shown in Fig. 2 tives MTX-Glu2 through -Glu5 was drug concentration dependent, the increased intracellular drug levels at higher doses being largely accounted for by a threefold increase in MTXPGs (30 nmol/mg at 10 MM vs. 10 nmol/g at 1 MM MTX). We next determined the efflux pattern of MTX-PGs from MPCs. Cells were first incubated with 1 or 10 MM MTX for 24 h and were then resuspended in drug-free medium. After incubation of cells for 1 h in drug-free medium (1-h efflux, Table III), total intracellular drug levels decreased. This decrease in intracellular drug was due predominantly to efflux of MTX (-Glul). Polyglutamate metabolites with three or more glutamyl moieties were preferentially retained in the absence of free extracellular drug. As shown in Fig. 2 B, after 24 h of efflux, little MTX-Glul and MTX-Glu2 were retained intracellularly, although sufficient MTX-Glu3, -Glu4, and -Glu5 were preferentially retained to continue to saturate intracellular binding capacity. Table III shows that after 24 h of incubation in 10 ,MM MTX and 24 h of efflux into drug-free medium, -85% of the remaining intracellular drug was accounted for by the higher molecular weight PG species. Only 5% of drug originally present as parent compound after 24 h of incubation was retained after the 24-h efflux period; 25% of Glu2 was retained; 40% of Glu3; 70% of Glu4; and nearly 100% of Glu5. Free drug in excess of that bound to DHFR (12.73±4.11 nM/g remained after 24-h incubation in drug-free media. However, after 24 h of exposure to 1 MM MTX, only small amounts of high molecular weight PGs were formed by bone marrow MPCs (Table II) . After 24 h of efflux in drug-free media, only 2.95±1.37 nmol/g of free drug were retained.
Cytotoxic effects of MTX-PGs on CFU-C formation. We next sought to determine the cytotoxic effects of retained MTX-PGs on the myeloid colony-forming ability of the MPC fraction. Cells were exposed to either 1 or 10 MAM MTX in complete media for 24 h in the presence of rescue nucleosides, and were then assessed for CFU-C survival using a medium that contained dialyzed FCS without added purines or pyrimidines. 24-h exposure to 1 MM MTX in the presence of rescue had no effect on subsequent CFIJ-C formation, whereas 24-h exposure to 10 MM drug under the same conditions resulted in a significant reduction to 65.2±8.7% of control (P < 0.001) in CFU-C formation (Table IV) .
MTX-PG formation and cytotoxicity in HL-60 cell line. In order to determine whether MTX-PG formation is associated with prolonged cytotoxic effect in MTX-sensitive myloid tumor cells and to determine that the rosetting conditions had no (Table V) , with an excess of 8.09 nmol/g of protein as free drug as compared with a free-drug level of only 2.95 nmol/g of protein in the bone marrow MPC (Table II) . Data in Table V also show that the panel of monoclonal antibodies had no effect on the ability of HL-60 to form MTX-PGs. The growth inhibition of colony formation of HL-60 cells after 24-h exposure to MTX is shown in Table VI . Cell numbers and viability, as determined by trypan blue exclusion, remained constant during the drug-exposure period itself, as cells were rescued from MTX cytotoxicity by exogenous thymidine and deoxyinosine. Consequently, any effect on cell growth noted thereafter in drug-and rescue-free medium represented the delayed cytotoxic effect of retained MTX-PGs. Even after exposure to 1 MM MTX, a concentration that had no effect on CFU-C formation, marked (97%) inhibition of HL-60 colony formation was observed.
Discussion
The present study demonstrates that normal bone marrow MPC form limited quantities of MTX-PGs in a concentrationand time-dependent pattern and that these metabolites are preferentially retained by myeloid precursors in direct proportion to PG chain length. At low MTX concentrations (1 MM), only small amounts of higher molecular weight MTX-PGs were formed by MPCs, free-drug concentrations exceeded binding capacity by only 2.95 nmol/g of protein after removal of free drug, and there was no delayed effect on CFU-C colony formation when cells were resuspended in drug-free media. At high MTX concentrations (10 AM), target enzyme in bone marrow MPC was saturated by retained, higher molecular weight MTX-PGs in a similar manner to HL-60 cells, and a 35% reduction in CFU-C formation was seen. The levels of MTX-PGs in MPC were 37-48% of those in the HL-60 tumor cell line under identical conditions of exposure. A direct correlation between chain length and MTX-PG retention was found in both normal bone marrow MPC and promyelocytic leukemia cells. After 24-h exposure to 1 MM MTX, HL-60 cells formed nearly twice the concentration of higher molecular weight PGs (MTX-Glu3, -Glu4, -Glu5). These PGs were retained in the absence of free extracellular drug (8.09 nmol of free drug/mg of protein at 24-h efflux) and continued to saturate the binding capacity, leading to nearly complete suppression (97%) of clonogenicity. Although these studies provide evidence for limited capacity of early myeloid cells to form MTX-PGs, the correlation of MTX-PG formation with toxicity to CFU-C is speculative because the CFU-Cs constituted only 1.4% of the cells, despite the enrichment of this preparation. However, in view of the absence of MTX-delayed cytotoxicity at drug levels of 1 4M
and modest toxicity to CFU-C at 10 MM, it is likely that MTX-PG formation is either equal to or less than that of the overall MPC fraction examined in this study.
The results of the present studies may be compared with those previously reported for other human tumor cell lines. Our previous studies of human breast cancer cell lines showed considerable PG synthesis and delayed cytotoxicity in a MTXsensitive cell line even at a low MTX concentration (2 MM) (18) . After 24-h incubation, the level of total intracellular drug in the MCF-7 cell line reached 95.4 nmol/g, and 55.4% (51.9 nmol/g) of drug was in the form of MTX-PGs. Preferential retention of MTX-PGs was noted after an additional 24-h incubation in drug-free media. In contrast, a MTX-resistant breast cancer cell line (MDA) synthesized small amounts of MTX-PGs (4.06 nmol/g) under the same conditions of exposure. A similar close relationship between MTX-PG formation and sensitivity to MTX has been reported in a study of three small-cell lung cancer cell lines (20). Levels of MTX-PGs in normal bone marrow MPC are considerably lower, even at a high MTX concentration (10 MM), than the levels of MTXPGs in the various MTX-sensitive tumor cell lines at 1-2 ,uM MTX. Thus, the selective effects of MTX on tumor cells as compared with bone marrow may be in part due to the limited capacity of myeloid precursors to form MTX-PGs. Additionally, a nearly twofold increase in DHFR binding capacity in MPC was noted after 24-h exposure to MTX. This fact might also be a significant factor contributing to the relative resistance of normal bone marrow cells to MTX.
The foregoing results may help to explain the selective effects of MTX for malignant cells versus bone marrow myeloid precursors. The inefficient formation of MTX-PGs by myeloid precursors at drug levels of 1 MM or below (the usual range of concentrations achieved by other than highdose regimens), may explain the rapid recovery of DNA synthesis in bone marrow when extracellular drug levels fall below the critical threshold of 1 X 10-8 M (32) . The recovery of DNA synthesis would be delayed in cells containing levels of MTX-PGs in excess of the DHFR binding capacity. Certainly factors other than MTX-PG formation influence cytotoxicity.
These include drug transport, the level of DHFR, and the activity of thymidylate synthetase (2 These investigators, however, did not use a purified bone marrow cell population. The bone marrow aspirate population is heterogeneous and contains myeloid cells at various stages of maturation, as well as erythroid precursors, lymphocytes, and monocytes. These cell populations may have different pharmacologic and metabolic properties. Thus, such a mixed cell population may not be optimal for examining drug metabolism by the specific cell population affected by MTX, namely the myeloid precursor pool. For this reason, purified immature MPCs were used in this study. The immune rosette technique allowed elimination of most mature granulocytes, monocytes, T and B lymphocytes, and erythroid precursors, and a much more homogeneous MPC population was obtained. Undifferentiated blasts were preferentially selected and accounted for 68%± 12% of the purified total cell population. These changes were associated with an -16-fold increase in cloning efficiency in the CFU-C assay, indicating co-purification of the clonogenic myeloid precursor cells. These purification techniques allowed more precise examination of MTX metabolism in normal myeloid precursors, and may be useful in examining bone marrow metabolism of other drugs as well. 
